Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 384

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 384
---
 and reimbursement The principal groups that DiamiR expects to pay for its molecular testing services include: •Biopharmaceutical companies conducting clinical trials; •Clinical centers, including memory, brain health and geriatric centers that will pay negotiated rates for their clinicians’ test orders; •Commercial third -partypayors, based on existing or novel Current Procedural Terminology (CPT) and/or PLA codes; •Government and private payors, with whom DiamiR plans to initiate a dialog and to submit relevant applications as soon as feasible; and •Patients and at -riskindividuals who pay co -payments, deductibles and other amounts that DiamiR is unable to collect from their health insurers. After this offering, DiamiR plans to expand its team with reimbursement and regulatory experts, and DiamiR will work diligently towards securing reimbursement based on current regulations. DiamiR plans on creating a clinical dossier compromised of peer -reviewpublications on the following 4 key areas: 1.Analytical Validation — The assay correctly and reproducibly tests for specific analytes/targets 2.Clinical Validation — The assay’s target analytes rule -inor rule -outa disease 3.Clinical utility — The test results in changes with physician behavior or patient treatment 4.Cost -effectivenessand economic health benefits — The test saves the healthcare system money, either by reducing unnecessary treatment, improving outcomes or other measures. A robust clinical dossier is a critical tool for successful reimbursement discussions with payors. DiamiR’s management team has experience with, and understands the process, and will focus its efforts to gain insurance coverage in a timely manner. 223 Accurate early diagnostics of AD will improve effectiveness of future cost of care for AD. The current cost of care for AD and AD related issues is estimated to be around $345B annually and is expected to reach $1Trillion by 2050. ____________ * https://www.alz.org/media/Documents/alzheimers -facts-and-figures .pdf Strategies and products designed for early identification of AD are key to reducing the financial burden of AD to payors, caregivers, and families of those impacted by this disease. Thus, the use of CogniMIR ®and DiamiR’s other future tests align with payors’ goals to improve the affordability and efficacy of diagnosis and treatment for AD. Other supportive publications on cost effectiveness of early intervention include: “Evaluation of the Cost -effectivenessof Drug Treatment for Alzheimer Disease in a